A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

@article{Vergote2014AP1,
  title={A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.},
  author={Ignace Vergote and A Oaknin and J F Baurain and Sumitra S Ananda and Shirley Wong and Xiaohong Su and Benjamin M. Wu and Zhandong Don Zhong and Douglas J. Warner and Antonio Cuevas Casado},
  journal={European journal of cancer},
  year={2014},
  volume={50 14},
  pages={2408-16}
}
AIM To evaluate the tolerability, pharmacokinetics and tumour response of first-line trebananib plus paclitaxel and carboplatin followed by trebananib maintenance in high-risk or advanced ovarian cancer. METHODS In this open-label phase 1b study, patients received intravenous (IV) trebananib 15 mg/kg administered weekly (QW) plus paclitaxel 175 mg/m(2) once every 3 weeks (Q3W) and carboplatin 6 mg/mL · min Q3W followed by trebananib 15 mg/kg QW monotherapy for 18 months. End-points were dose… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
3 Citations
35 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 35 references

A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1

  • BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae
  • European Cancer Congress
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…